/ Products / IHC / PRIMARY ANTIBODY / FLI-1(MRQ-1),MMab /

FLI-1(MRQ-1),MMab

FLI-1 is used to label Ewing's sarcoma/primitive neuroectodermal tumors, with specificity and sensitivity superior to CD99. It is also a new type of vascular endothelial marker, with specificity and sensitivity as good as CD31 and CD34. Its positive site is located in the nucleus and is easy to observe.

Intended Use

[Storage and Validity]

Store at 2~8°C. Avoid freezing.
Maintain temperature below room temperature during transport, ensuring it does not exceed one week.

Specification

Product Name	FLI-1(MRQ-1),MMab
Clone	MRQ-1
Catalog No.	CFM-0040
Positive Site	Nucleus
Applicable Tissue	Paraffin section
Pre-treatment	Heat retrieval
Format and Volume	Ready-to-use: 1mL, 3mL, 6mL

Download

Intended Use
Specification

Related Products

CNT330 Full Automatic Multiplex IHC Stainer

Optimize your IHC lab workflow with the CNT330 Full Automatic Multiplex IHC Stainer. This advanced system supports continuous operation, loading up to 30 slides across three independent frames simultaneously. Enjoy a fully automated process, including slice drying, deparaffination, antigen retrieval, and more, enhancing lab standardization and efficiency. Standalone modal.

Learn more

FSH(EP257),RMab

Follicle-stimulating hormone is a hormone secreted by the pituitary gland. In women, it can promote the proliferation and development of follicles; in men, it can promote the production of sperm. This antibody reacts with human FSH and is mainly used for the functional classification of pituitary adenomas and the diagnosis of pituitary adenomas and metastatic tumors.

Learn more

FOXP1(BP6112),RMab

FOXP1 protein is a winged-helix transcription factor that is upregulated during B-cell activation. FOXP1 is a prognostic indicator for diffuse large B- cell lymphoma, especially in germinal center-type diffuse large B-cell lymphoma, where positivity suggests a poor prognosis.

Learn more

Factor XIIIa(EP3372), RMab

Factor XIIIa is a β-globulin found in the blood. It is useful in the differential diagnosis of dermatofibroma (90%+), dermatofibrosarcoma protuberans (25%+), and desmoplastic malignant melanoma (0%+).

Learn more